Otitis externa: Providing relief while avoiding complications

Journal of Family Practice

Volumn 54, Issue 8, 2005, Pages 669-676

  Block, Stan L ^a,b,c  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM ACETATE; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ASTRINGENT AGENT; BUROW'S SOLUTION; CICLOPIROXOLAMINE; CIPRODEX; CIPROFLOXACIN; COCODAMOL; CORTICOSTEROID; FLOXIN OTIC; FLUCONAZOLE; GENTAMICIN; HYDROCORTISONE; NARCOTIC AGENT; NEOMYCIN; OFLOXACIN; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; THIOMERSAL; VOSOL; VOSOL OTIC;

ANTIBIOTIC THERAPY; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; CELLULITIS; DEBRIDEMENT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; EXTERNAL OTITIS; HUMAN; OTOTOXICITY; PATIENT COMPLIANCE; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT;

AMINOGLYCOSIDES; ANALGESICS; ANTI-INFECTIVE AGENTS, LOCAL; DRUG COMBINATIONS; DRUG HYPERSENSITIVITY; FLUOROQUINOLONES; HUMANS; OTITIS EXTERNA;

EID: 23444448221     PISSN: 00943509     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (56)

1. Agius AM, Pickles JM, Burch KL. A prospective study of otitis externa. Clin Otolaryngol 1992; 17:150-154.
2. Clark WB, Brook I, Bianki D, Thompson DH. Microbiology of otitis externa. Otolaryngol Head Neck Surg 1997; 116:23-25.
3. van Asperen I, de Rover CM, Schijven JF, Oetomo SB, Schellekens JF, van Leeuwen NJ, et al. Risk of otitis externa after swimming in recreational fresh water lakes containing Pseudomonas aeruginosa. BMJ 1995; 311:1407-1410.
4. Rowlands S, Devalia H, Smith C, Hubbard R, Dean A. Otitis externa in UK general practice: a survey using the UK General Practice Research Database. Br J Gen Pract 2001; 51:533-538.
5. Hawke M, Wong J, Krajden S. Clinical and microbiological features of otitis externa. J Otolaryngol 1984; 13:289-295.
6. Halpern MT, Palmer CS, Seidlin M. Treatment patterns for otitis externa. J Am Board Fam Pract 1999; 12:1-7.
7. Lang R, Goshen S, Kitzes-Cohen R, Sade J. Successful treatment of malignant external otitis with oral ciprofloxacin: report of experience with 23 patients. J Infect Dis 1990; 161:537-540.
8. Hannley MT, Denneny JC, Holzer SS. Use of ototopical antibiotics in treating 3 common ear diseases. Otolaryngol Head Neck Surg 2000; 122:934-940.
9. Cassisi N, Conn A, Davidson T, Witten BR. Diffuse otitis externa: clinical and microbiologic findings in the course of a multicenter study on a new otic solution. Ann Otol Rhinol Laryngol Suppl 1977; 86:1-16
10. Zikk D, Rapoport Y, Redianu C, Shalit I, Himmelfarb MZ. Oral ofloxacin therapy for invasive external otitis. Ann Otol Rhinol Laryngol 1991; 100:632-637.
11. Kimura AC, Pien FD. Head and neck cellulitis in hospitalized adults. Am J Otolaryngol 1993; 14:343-349.
12. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin Ther 2001; 23:1296-1310.
13. Urquhart J. Ascertaining how much compliance is enough with outpatient antibiotic regimens. Postgrad Med J 1992; 68(suppl 3):S49-S59.
14. Garrity JD, Halliday TC, Classman JM. Prevention of swimmer's ear by simple prophylactic regimen. Curr Ther Res Clin Exp 1974; 16:437-441.
15. Dadagian AJ, Hicks JJ, Ordonez GE, Glassman JM. Treatment of otitis externa: a controlled bacteriological-clinical evaluation. Curr Ther Res Clin Exp 1974; 16:431-436.
16. Lambert IJ. A comparison of the treatment of otitis externa with 'Otosporin' and aluminium acetate: a report from a services practice in Cyprus. J R Coll Gen Pract 1981; 31:291-294.
17. Clayton MI, Osborne JE, Rutherford D, Rivron RP. A double-blind, randomized, prospective trial of a topical antiseptic versus a topical antibiotic in the treatment of otorrhoea. Clin Otolaryngol 1990; 15:7-10
18. Kleinerman ES, Knowles RD, Lachman LB, Gutterman JU. Effect of recombinant granulocyte/macrophage colony-stimulating factor on human monocyte activity in vitro and following intravenous administration. Cancer Res 1988; 48:2604-2609.
19. van Balen FA, Smit WM, Zuithoff NP, Verheij TJ. Clinical efficacy of three common treatments in acute otitis externa in primary care: randomised controlled trial. BMJ 2003; 327:1201-1205.
20. Jones RN, Milazzo J, Seidlin M. Ofloxacin otic solution for treatment of otitis externa in children and adults. Arch Otolaryngol Head Neck Surg 1997; 123:1193-1200.
21. Pistorius B, Westberry K, Drehobl M. Prospective, randomized, comparative trial of ciprofloxacin otic drops, with or without hydrocortisone, vs. polymyxin B-neomycin-hydrocortisone otic suspension in the treatment of acute diffuse otitis externa. Infect Dis Clin Pract 1999; 8:387-395.
22. Hooper DC. Quinolones. In: Mandell G, Bennett J, Dolin R, eds. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Philadelphia, Pa: Churchill Livingstone, 2000:404-413.
23. Blake P, Matthews R, Hornibrook J. When not to syringe an ear. N Z Med J 1998; 111:422-424.
24. Chambers H. Antimicrobial agents: the aminoglycosides. In: Hardman J, Limbird L, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 2001:1219-1238.
25. Schmitz F-J, Verhoef J, Fluit AC. Prevalence of aminoglycoside resistance in 20 European university hospitals participating in the European SENTRY Antimicrobial Surveillance Programme. Eur J Clin Microbiol Infect Dis 1999; 18:414-421.
26. Dohar JE, Kenna MA, Wadowsky RM. In vitro susceptibility of aural isolates of Pseudomonas aeruginosa to commonly used ototopical antibiotics. Am J Otol 1996; 17:207-209.
27. Chambers H. Antimicrobial agents: protein synthesis inhibitors and miscellaneous antibacterial agents. In: Hardman J, Limbird L, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 2001:1239-1271.
28. Goldblatt EL. Efficacy of ofloxacin and other otic preparations for acute otitis media in patients with tympanostomy tubes. Pediatr Infect Dis J 2001; 20:116-119.
29. Bovelacci A, Montini G, Ramacciotti PG. Changes in resistance to aminoglycoside antibiotics of different bacterial strains isolated during the period 1978 to 1983. Netilmicin as alternative therapy. Chemioterapia 1985; 4:439-444.
30. Courcol RJ, Pinkas M, Martin GR. A seven year survey of antibiotic susceptibility and its relationship with usage. J Antimicrob Chemother 1989; 23:441-451.
31. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis 2001; 7:178-182.
32. Wright CG, Meyerhoff WL. Ototoxicity of otic drops applied to the middle ear in the chinchilla. Am J Otolaryngol 1984; 5:166-176.
33. Barlow DW, Duckert LG, Kreig CS, Gates GA. Ototoxicity of topical otomicrobial agents. Acta Otolaryngol 1995; 115:231-235.
34. Jinn TH, Kim PD, Russell PT, Church CA, John EO, Jung TT. Determination of Ototoxicity of common otic drops using isolated cochlear outer hair cells. Laryngoscope 2001, 111:2105-2108.
35. Wong DL, Rutka JA. Do aminoglycoside otic preparations cause ototoxicity in the presence of tympanic membrane perforations? Otolaryngol Head Neck Surg 1997; 116:404-410.
36. Marais J, Rutka JA. Ototoxicity and topical eardrops. Clin Otolaryngol 1998; 23:360-367.
37. Bath AP, Walsh RM, Bance ML, Rutka JA. Ototoxicity of topical gentamicin preparations. Laryngoscope 1999; 109:1088-1093.
38. Van Ginkel CJ, Bruintjes TD, Huizing EH. Allergy due to topical medications in chronic otitis externa and chronic otitis media. Clin Otolaryngol 1995; 20:326-328.
39. Dickel H, Taylor JS, Evey P, Merk HF. Delayed readings of a standard screening patch test tray: frequency of "lost," "found," and "persistent" reactions. Am J Contact Dermal 2000; 11:213-217.
40. Suneja T, Belsito DV. Thimerosal in the detection of clinically relevant allergic contact reactions. J Am Acad Dermatol 2001; 45:23-27.
41. Manzini BM, Ferdani G, Simonetti V, Donini M, Seidenari S. Contact sensitization in children. Pediatr Dermatol 1998; 15:12-17.
42. Barros MA, Baptista A, Correia TM, Azevedo F. Patch testing in children: a study of 562 schoolchildren. Contact Dermatitis 1991; 25:156-159.
43. Roland PS, Stroman DW. Microbiology of acute otitis externa. Laryngoscope 2002; 112:1166-1177.
44. Gales AC, Reis AO, Jones RN. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines. J Clin Microbiol 2001; 39:183-190.
45. Torum B, Block SL, Avila H, Montiel F, Oliva A, Quintanilla W, et al. Efficacy of ofloxacin otic solution once daily for 7 days in the treatment of otitis externa: a multicenter, open-label, phase III trial. Clin Ther 2004; 26:1046-1054.
46. Alexandrakis G, Alfonso EC, Miller D. Shifting trends in bacterial keratitis in south Florida and emerging resistance to fluoroquinolones. Ophthalmology 2000; 107:1497-1502.
47. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmology 1999; 106:1313-1318.
48. Chaudhry NA, Flynn HW Jr, Murray TG, Tabandeh H, Mello MO Jr, Miller D. Emerging ciprofloxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol 1999; 128:509-510.
49. Russell PT, Church CA, Jinn TH, Kim DJ, John EO, Jung TT. Effects of common topical otic preparations on the morphology of isolated cochlear outer hair cells. Acta Otolaryngol 2001; 121:135-139.
50. Pipek R, Vulfsons S, Wolfovitz E, Har-Shai Y, Taran A, Peled IJ. Case report: ofloxacin-induced hypersensitivity vasculitis. Am J Med Sci 1996; 311:82-83.
51. Reaño M, Vives R, Rodriguez J, Daroca P, Canto G, Fernandez J, Ciprofloxacin-induced vasculitis. Allergy 1997; 52:599-600.
52. Ciprodex® [manufacturer's prescribing information], Fort Worth, Tex: Alcon Laboratories, Inc, 2003.
53. Roland PS, Pien FD, Schultz CC, Henry DC, Conroy PJ, Wall GM, et al. Efficacy and safety of topical ciprofloxacin/dexamethasone versus neomycin/polymyxin B/hydrocortisone for otitis externa. Curr Med Res Opin 2004; 20:1175-1183.
54. Burden AD, Beck MH. Contact hypersensitivity to topical corticosteroids. Br J Dermatol 1992; 127:497-500.
55. Dooms-Goossens A, Morren M. Results of routine patch testing with corticosteroid series in 2073 patients. Contact Dermatitis 1992; 26:182-191.
56. Bircher AJ, Thurlimann W, Hunziker T, et al. Contact hypersensitivity to corticosteroids in routine patch test patients. A multi-centre study of the Swiss Contact Dermatitis Research Group. Dermatology 1995; 191:109-114.